HOME >> BIOLOGY >> NEWS
'Modular' leukemia drug shows promise in early testing

COLUMBUS , Ohio -- A new type of engineered drug candidate has shown promise in treating chronic lymphocytic leukemia in both test tube and early animal tests, a new study shows.

The agent represents a new class of agents called small modular immunopharmaceuticals. Called CD37-SMIP, the agent targets a protein called CD37 on the surface of these leukemia cells.

The study shows that the agent can successfully attach to the protein on the leukemia cells and kill them. The agent works both by triggering the cells' self-destruction and by causing a particular class of immune cells to attack them.

In an animal model, the agent worked equally as well as the drug rituximab, now routinely used to treat chronic lymphocytic leukemia (CLL) patients. Rituximab targets a different protein on leukemia cells.

The study by researchers at the Ohio State University Comprehensive Cancer Center was published online in the journal Blood.

Our findings have significant implications for the treatment of CLL and related malignancies, says principal investigator John C. Byrd, director of the hematologic malignancies program at Ohio State 's James Cancer Hospital and Solove Research Institute.

Overall, Byrd says, the findings indicate that this could be an effective agent for treating CLL and other malignancies, such as non-Hodgkin's lymphoma and acute lymphoblastic leukemia when they have expression of the CD37 protein.

The laboratory portion of the study used CLL cells from patients, laboratory-grown non-Hodgkin's lymphoma cells and acute lymphocytic leukemia cells.

This research showed that the agent kills leukemia cells directly by triggering their self-destruction through the process of apoptosis.

The study also found that this self-destruction happens differently from how other drugs cause apoptosis. Most drugs cause cells to self-destruct by triggering a cell mechanism that requires en
'"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University
28-Jun-2007


Page: 1 2

Related biology news :

1. Adult survivors of childhood leukemia exercise less, worsening high risk for obesity and illness
2. Scientists gain important insights into acute promyelocytic leukemia
3. Researchers discover inherited mutation for leukemia
4. Inherited genes linked to toxicity of leukemia therapy
5. Unstable leukemia stem cells may predispose patients to drug resistance
6. Tree rings show elevated tungsten coincides with Nevada leukemia cluster
7. Cancer scientists create human leukemia process to map how disease begins, progresses
8. Antioxidant found in many foods and red wine is potent and selective killer of leukemia cells
9. Knocking out survival protein could aid leukemia treatment
10. Massey researchers induce cell death in leukemia
11. Progress toward a targeted therapy for a specific form of leukemia

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/29/2020)... RESEARCH TRIANGLE PARK, N.C. (PRWEB) , ... January ... ... as a partner to lead the new Analytics and Data Sciences practice, providing ... life sciences clients. Burke’s appointment was announced by Mike Townley, co-founder and Managing ...
(Date:1/27/2020)... ... January 27, 2020 , ... On Thursday, February 20, 2020 ... Sciences, Reed Tech and Richard Castle, Global Account Manager Medical Device at ... procedure, other topics include EU MDR timing deadlines, best practices in creating and submitting ...
(Date:1/23/2020)... ... 23, 2020 , ... GIOSTAR/HEAMGEN has developed and ... The red blood cells are made utilizing a bioreactor that permits the ... and replaces the need for a human blood donor. GIOSTAR/HEAMGEN mature ...
Breaking Biology News(10 mins):
(Date:1/24/2020)... , ... January 24, 2020 , ... The plastic and ... Surgery Center in New Jersey epitomize the notion that plastic surgery is much more ... characterized in popular media. , Over the last 20 years NJ Top Docs, Dr. ...
(Date:1/23/2020)... ... January 22, 2020 , ... Ideal ... cosmetic surgery industry at two recent North American investor forums specializing in medical ... Genuity Medical Technologies & Diagnostics Forum on November 21, 2019 in New York ...
(Date:1/22/2020)... DIEGO (PRWEB) , ... January 21, 2020 , ... ... to challenges with the precision of Genome editing. The partners have agreed to ... control (QC) of CRISPR research, agricultural, and pre-clinical programs. Over the longer-term, the ...
(Date:1/10/2020)... ... January 09, 2020 , ... Phlexglobal, the ... the acquisition of Cunesoft, a move that expands the company’s portfolio of best-of-breed ... sciences companies. , Based in Munich, Germany, Cunesoft provides intelligent software and expert ...
Breaking Biology Technology:
Cached News: